Recent studies have shown that AhR endogenous agonist levels are significantly lower in MS patients compared to healthy controls and lower AhR agonist levels are correlated with neurological dysfunction and disease severity [21, 22], implying that AhR may play an essential role in the pathogenesis of MS. This evidence concerns the gene AHR and myeloid sarcoma.